Abstract
INTRODUCTION This retrospective study investigates whether exposition to levodopa/carbidopa (LA/CA) medication is associated with modified Alzheimer’s disease (AD) trajectories.
METHODS Multivariate analysis used cerebrospinal fluid (CSF) biomarker information included in the National Alzheimer’s Coordinating Center Uniform Data Set for subjects with normal cognition (NC), mild cognitive impairment (MCI) and dementia (DE). Survival analyses examined the progression to MCI/DE and death events.
RESULTS LA/CA use is associated with lower levels of CSF amyloid beta, phosphorylated tau (P-tau) and total Tau. After adjusting for age, sex and APOE ε4 allele presence, that effect was quantified by negative coefficients of the fitted linear mixed models − P values <0.01 in all cases except for P-tau in the MCI subgroup (P=0.02). No similar effects were identified for other antiparkinsonian drugs. Exposition to LA/CA decreased the progression from MCI to DE (P=0.03).
DISCUSSION The identified effects of LA/CA exposition on AD biomarkers and progression deserve further investigation in controlled clinical trials.
Competing Interest Statement
The authors declare the following competing interests: ZS, SMR and PMM are co-inventors in provisional patent applications for the use of low-dose levodopa formulations for the treatment of neurodegenerative disorders.
Funding Statement
This work was funded by National Funds through FCT - Fundação para a Ciência e a Tecnologia, I.P., under the project UIDB/04293/2020 and PTDC/QUICOL/2444/2021. PMM is supported by FCT CEECIND/03750/2017/CP1386/CT0014 (https://doi.org/10.54499/CEECIND/03750/2017/CP1386/CT0014).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All individual-level data had been de-identified prior to its use in this study. This study does not require additional ethical approval beyond the approvals given for inclusion in the historical cohorts, including informed consent obtained from each participant.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
